United Therapeutics
UTHR
402 hedge funds and large institutions have $7.78B invested in United Therapeutics in 2021 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 117 increasing their positions, 160 reducing their positions, and 40 closing their positions.
113% more call options, than puts
Call options by funds: $48.6M | Put options by funds: $22.8M
35% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 40
7% more capital invested
Capital invested by funds: $7.28B → $7.78B (+$507M)
3% more funds holding
Funds holding: 391 → 402 (+11)
0.58% less ownership
Funds ownership: 97.82% → 97.24% (-0.58%)
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
27% less repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 160
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$105M |
| 2 |
PA
Perceptive Advisors
New York
|
+$84.1M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$53.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$45M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$76M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$55.8M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$46.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$45.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.8M |
UTHR Hedge Fund Activity: Q2 2021 in Review
402 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2021, worth a combined $7.78B — up 7% from $7.28B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new UTHR positions and 40 closed out — a net gain of 14 holders — while 117 added to existing stakes and 160 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $105M. The largest seller was Consonance Capital Management, cutting an estimated $76M.
- 402 institutional investors held United Therapeutics (UTHR) as of Q2 2021, up from 391 in Q1 2021.
- Funds reported $7.78B of United Therapeutics stock for Q2 2021, up 7% quarter-over-quarter.
- 54 funds opened new United Therapeutics positions in Q2 2021 and 40 closed out, a net change of +14 holders.
- The largest United Therapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $105M added.
- The largest United Therapeutics seller in Q2 2021 was Consonance Capital Management, an estimated $76M sold.
Based on aggregated 13F filings for Q2 2021.